Proactive Investors - Run By Investors For Investors

US billionaire Robert Duggan to invest US$25mln into Summit Therapeutics

Duggan was the boss of Pharmacyclics and oversaw the company’s US$21bn sale to US pharma giant AbbVie back in 2015
us dollar
Duggan will hold 48.8% of Summit’s shares once the investment goes through

A US healthcare entrepreneur is set to take a large stake in Summit Therapeutics PLC (LON:SUMM) after agreeing to pump US$25mln into the antibiotics specialist.

Robert Duggan was the chief executive and chairman of Pharmacyclics before it was sold to pharma giant AbbVie Inc (NYSE:ABBV) for US$21bn in 2015.

Through Pharmacyclics, the billionaire oversaw the development of ibrutinib (Imbruvica), a cancer drug which notched up sales of more than US$2.5bn last year.

READ: Summit well-funded as it gears up for ridinilazole phase III trial

He has agreed to pay US$1.60 for 15.63mln Summit American depositary shares – a 32% premium to the quoted Nasdaq price on Friday. The deal is equivalent to 78.13mln ordinary shares at roughly 25p each.

The purchase will take Duggan’s stake, which sat at just 0.2% before, to 48.8%.

Typically, any shareholder who owns more than 30% of a company’s shares is required to make a formal offer to the other investors.

Duggan doesn’t want to do that this time though, and his investment is conditional upon shareholders voting to approve a waiver allowing him to not make such an offer.

Assuming investors vote with the board and the investment goes ahead as planned, Summit will use the money to begin patient enrolment into the phase III clinical trial of its ridinilazole C Difficile treatment.

The fresh capital will also go towards completing investigational new drug (IND) application-enabling studies for SMT-571 – the company’s gonorrhoea candidate.

Duggan’s investment ‘speaks volumes’

On top of all that, it will also be used to accelerate the development of treatments for hospital-acquired superbugs, known as ESKAPE pathogens.

Summit estimates that the investment will extend its cash runway through to the end of January 2020.

“Mr Duggan is a seasoned healthcare entrepreneur and investor whose proposed investment into our company speaks volumes about the potential that our new mechanism antibiotics have in addressing serious infectious diseases,” said chief executive Glyn Edwards.

“We are thrilled with his commitment to Summit and look forward to advancing our programmes targeting infections caused by C. difficile, N. gonorrhoea and ESKAPE pathogens and showing significant advantages over current standards of care.”

In a separate statement, Summit confirmed chief financial officer Erik Ostrowski is to step down from his role at the end of the month to pursue another opportunity.

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

parsortix
February 01 2019
The cancer detection device is on track to finish a key clinical study in the first quarter of 2019, but in the meantime, it has shown promise in detecting abnormalities in unborn children
porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use